We are live on ! Find out more
NVS icon

Novartis

1,172 hedge funds and large institutions have $24.4B invested in Novartis in 2019 Q4 according to their latest regulatory filings, with 156 funds opening new positions, 412 increasing their positions, 387 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

184% more first-time investments, than exits

New positions opened: 156 | Existing positions closed: 55

64% more funds holding in top 10

Funds holding in top 10: 1423 (+9)

55% more call options, than puts

Call options by funds: $200M | Put options by funds: $129M

15% more capital invested

Capital invested by funds: $21.2B → $24.4B (+$3.18B)

8% more funds holding

Funds holding: 1,0901,172 (+82)

6% more repeat investments, than reductions

Existing positions increased: 412 | Existing positions reduced: 387

0.54% more ownership

Funds ownership: 9.57%10.11% (+0.54%)

Holders
1,172
Holders Change
+82
Holders Change %
+7.52%
% of All Funds
23.09%
Holding in Top 10
23
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+64.29%
% of All Funds
0.45%
New
156
Increased
412
Reduced
387
Closed
55
Calls
$200M
Puts
$129M
Net Calls
+$71M
Net Calls Change
+$62.6M
Name Holding Trade Value Shares
Change
Change in
Stake
FHA
226
First Horizon Advisors
Tennessee
$5.71M +$300K +3,342 +6%
OWD
227
Osborn Williams & Donohoe
Ohio
$5.62M -$197K -2,200 -4%
Federated Hermes
228
Federated Hermes
Pennsylvania
$5.62M -$191K -2,128 -3%
Geode Capital Management
229
Geode Capital Management
Massachusetts
$5.58M -$90.7K -1,011 -2%
ARMC
230
American Research & Management Company
Massachusetts
$5.55M -$85.2K -950 -2%
AG
231
Advisor Group
Arizona
$5.54M -$30.9K -344 -0.6%
SSA
232
Schonfeld Strategic Advisors
New York
$5.5M +$5.21M +58,107 New
FTIOP
233
Fiduciary Trust International of Pennsylvania
Pennsylvania
$5.48M -$189K -2,110 -4%
KeyBank National Association
234
KeyBank National Association
Ohio
$5.43M +$99.2K +1,105 +2%
Cambridge Investment Research Advisors
235
Cambridge Investment Research Advisors
Iowa
$5.4M +$342K +3,816 +7%
SC
236
Scotia Capital
Ontario, Canada
$5.33M +$197K +2,195 +4%
BCM
237
Bourgeon Capital Management
Connecticut
$5.24M -$97.8K -1,090 -2%
TAM
238
Tradition Asset Management
Virginia
$5.17M +$675K +7,523 +16%
CTA
239
Chesley Taft & Associates
Illinois
$5.16M -$90.6K -1,010 -2%
GCM
240
Garland Capital Management
Washington
$5.14M -$8.97K -100 -0.2%
PGFC
241
Peapack-Gladstone Financial Corp
New Jersey
$5.13M +$37.9K +422 +0.8%
PSUF
242
People's United Financial
Connecticut
$5.03M -$233K -2,599 -5%
HA
243
Hamel Associates
New Jersey
$5.02M -$58.6K -653 -1%
DMIC
244
Dixon Mitchell Investment Counsel
British Columbia, Canada
$4.88M +$94.8K +1,057 +2%
PAM
245
Private Asset Management
California
$4.81M -$74K -825 -2%
MML Investors Services
246
MML Investors Services
Massachusetts
$4.74M +$540K +6,023 +14%
CCT
247
Country Club Trust
Missouri
$4.74M -$45.3K -505 -1%
William Blair Investment Management
248
William Blair Investment Management
Illinois
$4.72M +$22.1K +246 +0.5%
GAM
249
Griffin Asset Management
New York
$4.68M -$6.73K -75 -0.2%
ZCA
250
Zeke Capital Advisors
Pennsylvania
$4.68M +$42.4K +473 +1%

NVS Hedge Fund Activity: Q4 2019 in Review

1,172 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2019, worth a combined $24.4B — up 15% from $21.2B a quarter earlier.

Buyers outnumbered sellers: 156 funds opened new NVS positions and 55 closed out — a net gain of 101 holders — while 412 added to existing stakes and 387 trimmed.

The largest buyer was Loomis, Sayles & Company, adding an estimated $284M. The largest seller was Dodge & Cox, cutting an estimated $140M.

  • 1,172 institutional investors held Novartis (NVS) as of Q4 2019, up from 1,090 in Q3 2019.
  • Funds reported $24.4B of Novartis stock for Q4 2019, up 15% quarter-over-quarter.
  • 156 funds opened new Novartis positions in Q4 2019 and 55 closed out, a net change of +101 holders.
  • The largest Novartis buyer in Q4 2019 was Loomis, Sayles & Company, an estimated $284M added.
  • The largest Novartis seller in Q4 2019 was Dodge & Cox, an estimated $140M sold.

Based on aggregated 13F filings for Q4 2019.